Uromigos
@Uromigos
Followers
6,740
Following
381
Media
439
Statuses
1,670
The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
Worldwide
Joined February 2017
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
AioonMay LOVE ORBIT
• 120127 Tweets
#SixTONESANN
• 83973 Tweets
#Venue101EXTRA
• 81658 Tweets
FULL TIME
• 71861 Tweets
Manchester United
• 56368 Tweets
Brentford
• 49688 Tweets
Kudus
• 41654 Tweets
Man U
• 39205 Tweets
Spurs
• 34986 Tweets
Ten Hag
• 33540 Tweets
Cáncer de Mama
• 33174 Tweets
#MUNBRE
• 26944 Tweets
Garnacho
• 24920 Tweets
#안녕_이한이_생일이에요
• 22835 Tweets
ジェシー
• 20009 Tweets
Newcastle
• 19765 Tweets
West Ham
• 17145 Tweets
Rashford
• 16531 Tweets
#트와이스와_원스의_9번째_연대
• 15675 Tweets
De Ligt
• 14024 Tweets
Leicester
• 12971 Tweets
Magesi
• 12015 Tweets
Hojlund
• 11743 Tweets
Southampton
• 11356 Tweets
A summary of the ADC session at
#UromigosLive24
with
@apolo_andrea
@shilpaonc
@PGrivasMDPhD
@tompowles1
&
@kalasri3
4
48
125
🧵
#UromigosLive
#ProstateCancer
Poll: Emerging therapeutic approaches for the treatment of mHSPC ‼️👇POLLS TO FOLLOW‼️ (1/3) 👇
6
42
88
Paper of the month:
@JoshMeeks
develops 5 subgroups based on RNA signatures to predict response a PD(L)1 in urothelial cancer (figure bellow). Multiple mechanisms of response/resistant creates a complex picture which Josh simplifies .
2
36
88
🧵
#UromigosLive
#ProstateCancer
Poll: You've seen data for mHSPC doublet trials👇 from
#CHAARTED
#Stampede
#Latitude
#TITAN
#ARCHES
#ENZAMET
and triplet trials 👇from
#PEACE1
#ARASENS
. No trial compared ADT + ARAT versus ADT + ARAT + Docetaxel. ‼️POLLS TO FOLLOW‼️ (1/6)
6
57
84
@brian_rini
and
@tompowles1
have launched a new website, , featuring podcasts, videos, Uromigos Live annual meeting material and much more! Visit soon for
#GU23
content.
@montypal
@shilpaonc
@PGrivasMDPhD
@neerajaiims
@drenriquegrande
@DrChoueiri
3
18
84
Prostate cancer poster highlights
#asco22
. Which patients benefit from docetaxel chemotherapy
@ChrisSweens1
5
24
84
🧵
#UromigosLive
#ProstateCancer
: Most successful strategies for developing anticancer combination Rx commonly adhere to the following👉1⃣ Distinct MOA 2⃣ Significant single agent activity3⃣ Non-overlapping toxicities ➡️Ex. BEP for germ cell tumors. mHSPC following the example‼️
1
34
80
1st line bladder cancer, what just happened?
#nashvillelive
Was nivo/cis data expected? Who shouldn’t get EV pembro? How much does maintenance avelumab help? What next now EV/pembro is standard treatment?
@DrRosenbergMSK
@MattGalsky
@shilpaonc
👉
1
27
79
ASCO23 GU highlights. What’s changed in prostate (PARPi, PEACE1, ICECAP, AI pathology) - bladder (THOR and VESPER) - renal (CONTACT3) please give us feedback - many thanks
@brian_rini
4
12
79
#UromigosLive
2023 will feature a 'Rising Stars' session this year. Promoting the next generation of GU Oncology research is part of our core mission.
3
22
75
Pembrolizumab is approved in BCG refractory NMIBC. A new chapter begins for these patients. These drugs seem to work best in earlier disease. Randomised trials will be needed to confirm the benifit. We also need biomarkers as <50% benifit.
4
45
69
#ESMO
Clinical Practice Guidelines eUpdates just released for immune and targeted therapy in bladder cancer
#urothelialcancer
👉
#blcsm
@myESMO
#OncoAlert
#niioncologii
1
43
69
2nd attempt a showing A prize winning prostate cancer poster
@neerajaiims
discussed by
@Daniel_J_George
2
17
60
The Cancer Immunity Cycle has been updated! Listen to the details here as Ira Mellman breaks down this update.
1
25
59
APCCC debate with Thomas Zilli and Pierre Blanchard covering radiation therapy for metastatic disease from Lugano. Thanks to
@neerajaiims
for help with the tweet.
#APCCC2024
@OncoAlert
.
2
24
58
🧵
#UromigosLive
#KidneyCancer
Poll 1: You've seen the data for adjuvant therapy at
#ESMO22
from
#CM914
,
#IMmotion010
&
#PROSPER
, summarized against
#KN564
below. No
@myESMO
data was +, but updated data from
#KN564
in
@TheLancetOncol
continues to hold. ‼️POLLS TO FOLLOW‼️ (1/6)
1
33
57
Last golden ticket
#UromigosLive
is up for grabs.The best new photo with the Uromigos name in a selfie wins-a scribbled bit of paper is ok. It’s for developing doctors but anyone can enter & pick a person of their choice,so even
@ChrisSweens1
@DrChoueiri
@Silke_Gillessen
can win
4
11
56
📢
#UromigosLive
#KidneyCancer
Excellent discussion on perioperative strategies in
#RCC
w
@TiansterZhang
@tompowles1
@brian_rini
@montypal
#AxelBex
#DavidMcDermot
!
🎖️A round of applause to
@TiansterZhang
for winning the Golden Kidney prize with her future adjuvant study design!
1
19
50
50,000 uromigos listens in our first year. Thanks to all those who have taken part and a huge thanks to the audience who have persisted with us despite all the shortcomings.....
0
11
54
1/6 The NIAGRA perioperative durvalumab trial in muscle invasive bladder cancer was positive for EFS and OS
#UromigosLive24
. Shortcomings and future data also discussed. 84% thought this was the new standard of care. There are two other similar trials with PD-1 inhibitors
1
28
54
Uromigos Rising Star series kicks off with Renee Saliby discussing her work on RNA signatures predicting response to therapy in advanced renal cancer
@ReneeSaliby
@DrChoueiri
2
12
54
🧵
#UromigosLive
#KidneyCancer
Poll 2:
#COSMIC313
was presented at
#ESMO22
by
@DrChoueiri
. HR was 0.73 for PFS (met primary EP); no OS data presented at
@myESMO
. Triplet w 3% CR, 43% RR.
@brian_rini
assembled this table stacking up data in I/P risk pts. ‼️POLLS TO FOLLOW‼️ (1/8)
3
23
53
#UromigosLive
meeting Livestream (all times Eastern US time):
*Friday, Sept 30 - Bladder Cancer: 2-3PM
*Saturday, Oct 1 - Prostate Cancer: 11AM-noon
- Renal Cancer: 3-4PM
Livestream link/detailed agenda to follow!
1
21
53
Imvigor130 (front line bladder chemo+atezo) is positive for PFS, with OS trending positive. PFS has not been easy to achieve previously in bladder. I have been more confident about OS, which will get there in time. A new standard of care I suspect. Tom
1
22
53
Adjuvant nivolumab in bladder cancer for everyone, some or none?
#UromigosLive
@PGrivasMDPhD
3
12
53
We’re having an interactive uromigos meeting in Nashville 30 Sept-1st Oct
@DrRanaMcKay
@MattGalsky
@neerajaiims
@DrRosenbergMSK
@Prof_Nick_James
@montypal
@TiansterZhang
@shilpaonc
@PGrivasMDPhD
@Daniel_J_George
@kalasri3
details in the podcast …
0
24
53
Rechallange with pembrolizumab in UC in those patients who complete 2 yrs of therapy or stop due to CR is associated with responses. A highly selected population. What does this mean in the adjuvant therapy setting?
#nashvillelive
@koshkin85
#ESMO2023
1
16
49
We love our Rising Stars! Terrific study designs all around. Save this tweet - you are probably sure to see some of these trials advance to P3 in the future, wouldn't you say
@PGrivasMDPhD
@morr316
@TDorffOnc
?
That's a wrap on the fantastic rising stars panel at
#UromigosLive
! Give it up for
@PBarataMD
,
@bergsa83
,
@anis_a_hamid
,
@AmandaNizamMD
, and
@DrKarineTawagi
!
1
4
26
0
21
50
We have 2 winners for the last Uromigos golden ticket.
@ReneeSaliby
(surfing) &
@EbrahimiHedyeh
(Hollywood) winning. Excellence from
@PGrivasMDPhD
+ friends(beach),
@montypal
in the pub
@shilpaonc
(& puppy)
@DrDanielHeng
(forest)
@zapatalaguadomd
listening to
@drenriquegrande
4
17
50
ctDNA data in RCC. Detectable and informative. More work needed, but a liquid biomarker is appealing.
@tompowles1
@brian_rini
#ctDNA
1
5
50
The positive CHMP decision for axitinib and pembrolizumab in front line renal cancer is great news for EU patients. High response rates (60%), long PFS (>15 months) and a 47% reduction in the risk of death, irrespective of risk group, makes it really attractive. Tom
0
15
48
Adjuvant therapy in renal cancer. Where we are now and what’s next?
@montypal
#UromigosLive
#nashville22
1
14
49
The 3rd Annual
#UromigosLive
conference will be in Nashville September 27/28. Amazing faculty including
@PGrivasMDPhD
@MattGalsky
@shilpaonc
@DrChoueiri
@TDorffOnc
@HHammersMD
@AlbigesL
@TiansterZhang
@morr316
and more!! Rising Stars, Uromigos Cup and some surprises!
@MdMashup
2
22
48
Our 2nd golden ticket winner for Uromigos Nashville’23 is Vadim Koshkin
@koshkin85
We are having a livestream debate on the treatment of 1st line bladder cancer (Nov 3rd) as Vadim suggested. Discussion of ESMO23 data.
@DrRosenbergMSK
@shilpaonc
@MattGalsky
@PGrivasMDPhD
4
14
47
The
#UromigosLive
#BladderCancer
Poll 3: We have come a long way in drug dev in
#BladderCancer
since the 1st approval of IO in 2016!
Tx paradigm in 2022 (1/3)👇
@tompowles1
@DrRosenbergMSK
@brian_rini
2
21
47
It is great to see years of kidney cancer development has resulted in overall survival being used as the primary endpoint and improvements achieved - unequivocal clinical benefit! Well done to all who have contributed over the many years
0
13
46
Our prostate cancer debate with Rana McKay and Kim Chi covers 1st line doublet vs triplet therapy. This video is a quick summary - the podcast has the detail...
1
12
47
@tompowles1
and
@brian_rini
are looking forward to the
@Uromigos
session at the World Conference on GU Cancers next weekend for a special session on the impact of recent data in GU cancers on community practice.
3
14
46
We’re doing it again. Uromigos Live 2023 in Nashville November 3-4. Live sessions, videos and podcasts . A
#uromigoscup
. Highlights from ESMO. New perspectives. Golden tickets for rising stars. Happy to hear your ideas
1
9
45
A fantastic meeting in Madrid. Imvigor130 was debated by the Spanish group who made such a huge contribution. Consensus on the significance of the results was elusive. Most seem keen to wait for significant OS before making changes. I’m inclined to agree.
#sogug1
#simposioSOGUG
0
4
45
@Silke_Gillessen
and
@ProfKHerrman
discuss predictive characteristics associated with response from the VISION study.
#ASCO2023
.
@morr316
0
6
44
#UromigosLive
Day 2
#ProstateCancer
session: The Changing Landscape of mHSPC Treatment 👇(1/2)
2
18
43
Estamos iniciando una serie de podcasts en español, Las Tres Amigas con Begoña, Cristina y Elena
@Ecastromarcos
@crisuarez08
@begopval
. Esperamos que os gusten. Aquí está el enlace al primer podcast.
@brian_rini
@drenriquegrande
@tompowles1
@cdanicas
0
9
43
#ESMO23
PSMAFore Ph3 trial results👉 Pluvicto (Lu177) shows ⬆️rPFS vs ARPI change in taxane-naïve mCRPC
#prostatecancer
(Pts with any PSMA neg lesions on PSMA PET were excluded)👉57% reduction in risk of progression 👇
@Uromigos
#UromigosLive
Find 5 Polls below 👇 (1/6)
1
20
36
Press release states this first line maintenance study achieves OS in the ITT population (cisplatin eligable and inelgable) and is therefore distinct from front line atezo/pembro which are currently limited to biomarker positive cisplatin ineligable.
1
17
42
🧵
#UromigosLive
#BladderCancer
Poll 1:
Adjuvant high-risk muscle-invasive UC
IMVigor010- atezo NEG for DFS & OS
CM274 nivo met DFS endpoint in ITT & PD-L1 >/=1% NO OS data--Poll to follow (1/3)
1
24
40
With this coming ASCO and emergence of many active therapies for GU cancers, I personally will be less inclined to be comfortable with phase 3 trials calling success with only a PFS benefit without a QoL benefit or proven surrogacy for OS. (Chris)
@ChrisSweens1
1
6
39
Bladder cancer Asco 2019: maintenance pembrolizumab after front line chemo delaying PFS. The first PFS positive immune therapy study. OS awaited. Big success. Also bevacizumab with chemo hitting PFS but not OS. Huge effort. Great investigator led studies from Gasky/Rosenberg.
0
12
39
The uromigos podcast tour had 16 stops in 5 continents. Chris Sweeneys discussion on biomarkers in Prostate cancer was the most popular.
0
9
39
Check out our APCCC podcasts with Jason Efstathiou and Piet Ost discuss the data for and against adjuvant radiotherapy.
2
10
38
There are not too many ways of getting tickets to
#UromigosLive2024
in September in Nashville, but winning the
@uromigos
darts 🎯 🎯 🎯 competition at the annual party is one. Dr Ovidio Calvo 🇪🇸 threw magic darts (only 1 actually) & cleaned up. Welcome to Nashville.
#worlddarts
1
8
38
We think this might be worth a quick listen. Urothelial Cancer Highlights from ASCO GU 2020
3
14
36
#UromigosLive24
will discuss IO after IO in RCC. Despite negative trials this practice persists. Do we need a post adjuvant trial of IO? How long after adjuvant pembro would you rechallenge? Do patients get only one good shot at IO?
1
13
38
Golden tickets 🎟️ for the Uromigos Nashville 23 meeting available. It’s for junior faculty and includes accommodation🏨 , ✈️ social events 🎺 etc. Send us ideas for a podcast + presenter. Reply to this tweet or site.
15
15
38
A late entry for the final UROMIGOS golden ticket
#nashvillelive
from RCC legend
@DrDanielHeng
It’s from a Canadian rain forest apparently. He’s not surfing, and I’m not sure about the predictive nature of his classification, but surely he is in with a chance
@montypal
2
7
37
In the 2nd podcast in the Rising Star series. Scott Haake described his work on ctDNA and methylation signatures in renal cancer. Please send us your nomination for the rising star series. We’re looking for 5 more in 2022.
@DrScottHaake
@KimrynRathmell
0
14
37
La segunda edicion de Temas de Actualidad en cancer GU en las islas canarias comienza hoy
@uro_oncologist
@g_develasco
@brian_rini
@tompowles1
2
7
37
Post
@myESMO
data by
@AndreaNecchi
on SunRise-1 TAR-200 in BCG-unresponsive NMIBC, CR 77! Impressive DoR. Poll to follow (1/2)
1
17
37
Team 🇺🇸 USA 🇺🇸 winning the Uromigos cup 🏆🏆🏆👍👍👍against Japan. Thanks to all the teams Mexico 🇲🇽 France 🇫🇷 Germany 🇩🇪 Netherlands 🇳🇱 and Canada 🇨🇦
#uromigosLive
2
6
37
Sequential tissue analysis after neoadjuvant atezolizumab shows dynamic changes with therapy. Baseline activated T cells predict response. Up regulation of fibroblast (FAP) and cell cycle genes predict resistance. TMB and PD-L1 seem less relevant
2
17
35
10,000 views for uromigos podcasts. Unexpected when one considers the quality of chairing by
@tompowles1
@brian_rini
and regular interruptions/poor sound quality. Some great presenters though.
@montypal
@ChrisSweens1
@DrChoueiri
@ERPlimackMD
@AlbigesL
@kalasri3
@Silke_Gillessen
1
7
36
Nick Vogelzang gives an overview of developments in kidney cancer from the start and key moments in his career as part of the uromigos Legend weekly series.
0
9
36
The CLEAR trial with Toni Choueiri
1
11
35
Great, very well done study, now the discussions will begin which AR targeted substance and which combinations should be added to ADT. It will be interesting to see the biological data of this study!
1
7
36
Dr Grivas
@PGrivasMDPhD
wiped the floor with me in a debate of PD-L1 vs 2nd generation biomarkers in Bladder Ca (TMB CD8 etc). TMB got a particularly rough ride. It appears PD-L1 will stand the test of time, probably in combination with other biomarkers (CD8) to enrich response.
2
0
36
9/21 (43%) pathological complete response rates for durvalumab and tremelimumab in operable urothelial bladder cancer at ASCO2019
#4551
. Single agent PD-(L)1 inhibitor response rates are 30-40% (~same as chemo). Immune combos could be even better. IO looks most active here.
0
9
34
An unanswered question in these guidelines is how to chose between Ipi/nivo and axi/pembro
New renal cancer guidelines recommending axitinib and pembrolizumab irrespective of IMDC risk group.
1
74
121
2
9
34
.
Amazing really - nothing for 40 years - then immune checkpoint inhibitors, FGFR and EV (ADCs) all in 5 years. I think, for the first time, most patients won’t be having chemotherapy as standard of care in the near future.
1
7
35
The standard of care for papillary RCC has evolved over the last few years. We discussed this at
#UromigosLive24
with
@tompowles1
,
@AlbigesL
,
@HHammersMD
and David McDermott. SUNNIFORECAST was presented at
#ESMO24
.
2
20
35
The new EAU guidelines recommending axitinib/pembrolizumab as front line therapy for metastatic RCC irrespective of IMDC risk group. Ipilimumab/nivolumab continues to be recommended in intermediate and poor risk pateints. So it’s PD-1 + VEGF or CTLA-4.
2
18
35
We have a 2nd golden ticket award winner
@AmandaNizamMD
for Nashville’22 . Amanda highlights ongoing uncertainty around the agenda and faculty.
@brian_rini
assures us the social events are maturing well.
0
8
35
Thanks to everyone who listens and especially the >100 guests who made these happen.
@Silke_Gillessen
@ChrisSweens1
@AlbigesL
@kalasri3
David and Christina.
1
3
34
@BraunMDPhD
talks about elegant single cell RNAseq data from the HCRN nivo RCC trial.
#ASCO23
0
15
34
Everything you wanted to know about PD-1/VEGF combination toxicity management in RCC but were afraid to ask.
@ERPlimackMD
1
11
33
I think the best data from KCA2018 was the incredibly impressive ipilimumab and nivolumab data in sarcomatoid RCC from 214. High complete responses of 18%. Long-term remissions and great PFS/OS. Must be considered the right choice for patients.
0
11
32
Sitravatinib plus nivo in refractory RCC. Solid responses and durability which I think is expected given VEGF+IO known activity. Hard to tell if this is anything more than that. Brian
0
13
30
NCCN has made axi/pembro a category 2A recommendation for favorable risk. This is a misinterpretation of a subset analysis. The HR for OS was 0.64 in this subset. The 95% CI overlapped 1 because there were 17 total events. We need as a field to stop overinterpreting forest plots!
1
16
33
Thank you to our
@X
audience for the great interactions during the start of
#UromigosLive
! Hats off to
@shilpaonc
,
@MattGalsky
,
@montypal
,
@DrRosenbergMSK
,
@neerajaiims
et al for supporting the meeting!
Give us your thoughts on our content by replying to tweets from
@Uromigos
!
1
13
32
🇯🇵 🇯🇵 Japan 🇯🇵 🇯🇵 are on their way to Nashville for the Uromigos Cup!! 🏆Congratulations to them and team 🇩🇪 🇳🇱 🇨🇦 for their brilliant answers . Bring on team LA
2
9
32
The FDA approved this quickly. Great for US patients. Hopefully it will be approved in Europe and ROW soon too. This first line maintenance approach has the lowest hazard ratios to date in metastatic UC.
FDA approves maintenance avelumab sequenced directly after 1st line chemo in advanced UC. A huge global effort with >200 sites. It’s great news for patients. Earlier treatment as part of 1st line therapy is more effective and more patients can benifit.
1
29
102
0
12
32
Team Japan 🇯🇵 🇯🇵 enters the Uromigos 🏆🏆🏆 to beat team LA in Nashville. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through sometimes ridiculous questions ranging from Sumo wrestling to axitinib PK data. Can they beat Canada 🇨🇦 🇨🇦
1
12
31
#UromigosLive
#BladderCancer
1L Poll 2: You've seen EV-103 Cohort K EV +pembro(P) vs EV mono for 1L cis-ineligibl mUC
@ESMO
EV+P showed ORR 64.5%, median DOR NR. Ph 3 EV-302 of EV+P vs platinum chemo ongoing (OS primary)‼️ POLL TO FOLLOW‼️(1/4)
1
17
31
